Top

Published in:

01-07-2016 | Original Article

Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-α

Authors: G. Brunetti, F. Papadia, A. Tummolo, R. Fischetto, F. Nicastro, L. Piacente, A. Ventura, G. Mori, A. Oranger, I. Gigante, S. Colucci, M. Ciccarelli, M. Grano, L. Cavallo, M. Delvecchio, M. F. Faienza

Published in: Osteoporosis International | Issue 7/2016

Abstract

Summary

In this study, we investigated the bone cell activity in patients with osteogenesis imperfecta (OI) treated and untreated with neridronate. We demonstrated the key role of Dickkopf-1 (DKK1), receptor activator of nuclear factor-κB ligand (RANKL), and tumor necrosis factor alpha (TNF-α) in regulating bone cell of untreated and treated OI subjects. These cytokines could represent new pharmacological targets for OI.

Introduction

Bisphosphonates are widely used in the treatment of children with osteogenesis imperfecta (OI) with the objective of reducing the risk of fractures. Although bisphosphonates increase bone mineral density in OI subjects, the effects on fracture incidence are conflicting. The aim of this study was to investigate the mechanisms underlying bone cell activity in subjects with mild untreated forms of OI and in a group of subjects with severe OI treated with cycles of intravenous neridronate.

Methods

Sclerostin, DKK1, TNF-α, RANKL, osteoprotegerin (OPG), and bone turnover markers were quantified in serum of 18 OI patients (12 females, mean age 8.86 ± 3.90), 8 of which were receiving cyclic intravenous neridronate, and 21 sex- and age-matched controls. The effects on osteoblastogenesis and OPG expression of media conditioned by the serum of OI patients and anti-DKK1 neutralizing antibody were evaluated. Osteoclastogenesis was assessed in cultures from patients and controls.

Results

DKK1 and RANKL levels were significantly increased both in untreated and in treated OI subjects with respect to controls. The serum from patients with high DKK1 levels inhibited both osteoblast differentiation and OPG expression in vitro. High RANKL and low OPG messenger RNA (mRNA) levels were found in lymphomonocytes from patients. High amounts of TNF-α were expressed by monocytes, and an elevated percentage of circulating CD11b-CD51/CD61+ osteoclast precursors was observed in patients.

Conclusions

Our study demonstrated the key role of DKK1, RANKL, and TNF-α in regulating bone cell activity of subjects with OI untreated and treated with bisphosphonates. These cytokines could represent new pharmacological targets for OI patients.

Marini JC (2001) Osteogenesis imperfecta. In: Behrman RE, Kliegman RM, Jensen HB (eds) Nelson textbook of pediatrics, 17th edn. Saunders, Philadelphia, pp 2336–2338

Forlino A, Cabral WA, Barnes AM, Marini JC (2011) New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol 7:540–557CrossRefPubMedPubMedCentral

Cheung MS, Glorieux FH (2008) Osteogenesis imperfecta: update on presentation and management. Rev Endocr Metab Disord 9:153–160CrossRefPubMed

Rohrbach M, Giunta C (2012) Recessive osteogenesis imperfecta: clinical, radiological, and molecular findings. Am J Med Genet C: Semin Med Genet 160C:175–189CrossRef

Rauch F, Travers R, Parfitt AM, Glorieux FH (2000) Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone 26:581–589CrossRefPubMed

Baron R, Gertner JM, Lang R, Vignery A (1983) Increased bone turnover with decreased bone formation by osteoblasts in children with osteogenesis imperfecta tarda. Pediatr Res 17:204–207CrossRefPubMed

Eghbali-Fatourechi G (2014) Bisphosphonate therapy in pediatric patients. J Diabetes Metab Disord 13:109CrossRefPubMedPubMedCentral

Dwan K, Phillipi CA, Steiner RD, Basel D (2014) Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 7:CD005088. doi:10.1002/14651858.CD005088.pub3

Land C, Rauch F, Glorieux FH (2006) Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta. J Bone Miner Res 21:374–379CrossRefPubMed

10.

Baron R, Kneissel M (2013) WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 19:1791–1792CrossRef

11.

Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM, Delius H, Hoppe D, Stannek P, Walter C, Glinka A, Niehrs C (2002) Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 417:664–667CrossRefPubMed

12.

Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D (2005) Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883–19887CrossRefPubMed

13.

Morvan F, Boulukos K, Clément-Lacroix P, Roman Roman S, Suc-Royer I, Vayssière B, Ammann P, Martin P, Pinho S, Pognonec P, Mollat P, Niehrs C, Baron R, Rawadi G (2006) Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 21:934–945CrossRefPubMed

14.

Qiang YW, Chen Y, Stephens O, Brown N, Chen B, Epstein J, Barlogie B, Shaughnessy JD Jr (2008) Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 112:196–207CrossRefPubMedPubMedCentral

15.

Dalbeth N, Pool B, Smith T, Callon KE, Lobo M, Taylor WJ, Jones PB, Cornish J, McQueen FM (2010) Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion. Arthritis Res Ther 12:R164CrossRefPubMedPubMedCentral

16.

Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, Richards WG, Schett G (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13:156–163CrossRefPubMed

17.

Sillence DO, Senn A, Danks DM (1979) Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 15:101–116CrossRef

18.

Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tatò L, Viapiana O, Adami S (2005) Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 20:758–763CrossRefPubMed

19.

Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R, Grummer-Strawn LM, Curtin LR, Roche AF, Johnson CL (2002) Centers for disease control and prevention 2000 growth charts for the united states: improvements to the 1977 national center for health statistics version. Pediatrics 109:45–60CrossRefPubMed

20.

Vignali DA (2000) Multiplexed particle-based flow cytometric assays. J Immunol Methods 243:243–255CrossRefPubMed

21.

Mori G, Ballini A, Carbone C, Oranger A, Brunetti G, Di Benedetto A, Rapone B, Cantore S, Di Comite M, Colucci S, Grano M, Grassi FR (2012) Osteogenic differentiation of dental follicle stem cells. Int J Med Sci 9:480–487CrossRefPubMedPubMedCentral

22.

Brunetti G, Faienza MF, Piacente L, Ventura A, Oranger A, Carbone C, Benedetto AD, Colaianni G, Gigante M, Mori G, Gesualdo L, Colucci S, Cavallo L, Grano M (2013) High dickkopf-1 levels in sera and leukocytes from children with 21-hydroxylase deficiency on chronic glucocorticoid treatment. Am J Physiol Endocrinol Metab 304:E546–554CrossRefPubMed

23.

Jang WG, Kim EJ, Kim DK, Ryoo HM, Lee KB, Kim SH, Choi HS, Koh JT (2012) BMP2 protein regulates osteocalcin expression via Runx2-mediated Atf6 gene transcription. J Biol Chem 287:905–915CrossRefPubMed

24.

Gatti D, Viapiana O, Adami S, Idolazzi L, Fracassi E, Rossini M (2012) Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone 50:739–742CrossRefPubMed

25.

Braga V, Gatti D, Rossini M, Colapietro F, Battaglia E, Viapiana O, Adami S (2004) Bone turnover markers in patients with osteogenesis imperfecta. Bone 34:1013–1016CrossRefPubMed

26.

Giordano P, Brunetti G, Lassandro G, Notarangelo LD, Luciani M, Mura RM, Lazzareschi I, Santagostino E, Piacente L, Ventura A, Cavallo L, Grano M, Faienza MF (2015) High serum sclerostin levels in children with haemophilia A. Br J Haematol. doi:10.1111/bjh.13481

27.

Lee N, Smolarz AJ, Olson S, David O, Reiser J, Kutner R, Daw NC, Prockop DJ, Horwitz EM, Gregory CA (2007) A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies. Br J Cancer 97:1552–1559CrossRefPubMedPubMedCentral

28.

Aicher A, Kollet O, Heeschen C, Liebner S, Urbich C, Ihling C, Orlandi A, Lapidot T, Zeiher AM, Dimmeler S (2008) The Wnt antagonist Dickkopf-1 mobilizes vasculogenic progenitor cells via activation of the bone marrow endosteal stem cell niche. Circ Res 103:796–803CrossRefPubMed

29.

Fujita K, Janz S (2007) Attenuation of WNT signaling by DKK-1 and −2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Mol Cancer 6:71CrossRefPubMedPubMedCentral

30.

Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, Pouli A, Katodritou E, Verrou E, Vervessou EC, Dimopoulos MA, Croucher PI (2006) Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 135:688–692CrossRefPubMed

31.

Rossini M, Viapiana O, Zanotti R, Tripi G, Perbellini O, Idolazzi L, Bonifacio M, Adami S, Gatti D (2015) Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis. Calcif Tissue Int 96:410–416CrossRefPubMed

32.

Rossini M, Viapiana O, Adami S, Fracassi E, Idolazzi L, Dartizio C, Povino MR, Orsolini G, Gatti D (2015) In patients with rheumatoid arthritis, DKK1 serum levels are correlated with parathyroid hormone, bone erosions and BMD. Clin Exp Rheumatol 33:77–83PubMed

33.

Zeitlin L, Fassier F, Glorieux FH (2003) Modern approach to children with osteogenesis imperfecta. J Pediatr Orthop B 12:77–87PubMed

34.

Kalajzic I, Terzic J, Rumboldt Z, Mack K, Naprta A, Ledgard F, Gronowicz G, Clark SH, Rowe DW (2002) Osteoblastic response to the defective matrix in the osteogenesis imperfecta murine (oim) mouse. Endocrinology 143:1594–1601CrossRefPubMed

35.

Zhang H, Doty SB, Hughes C, Dempster D, Camacho NP (2007) Increased resorptive activity and accompanying morphological alterations in osteoclasts derived from the oim/oim mouse model of osteogenesis imperfecta. J Cell Biochem 102:1011–1020CrossRefPubMedPubMedCentral

36.

Uveges TE, Collin-Osdoby P, Cabral WA, Ledgard F, Goldberg L, Bergwitz C, Forlino A, Osdoby P, Gronowicz GA, Marini JC (2008) Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors. J Bone Miner Res 23:1983–1994CrossRefPubMedPubMedCentral

37.

Li H, Jiang X, Delaney J, Franceschetti T, Bilic-Curcic I, Kalinovsky J, Lorenzo JA, Grcevic D, Rowe DW, Kalajzic I (2010) Immature osteoblast lineage cells increase osteoclastogenesis in osteogenesis imperfecta murine. Am J Pathol 176:2405–2413CrossRefPubMedPubMedCentral

38.

D’Eufemia P, Finocchiaro R, Celli M, Zambrano A, Tetti M, Villani C, Persiani P, Mari E, Zicari A (2008) High levels of serum prostaglandin E2 in children with osteogenesis imperfecta are reduced by neridronate treatment. Pediatr Res 63:203–206CrossRefPubMed

39.

Camacho NP, Raggio CL, Doty SB, Root L, Zraick V, Ilg WA, Toledano TR, Boskey AL (2001) A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta. Calcif Tissue Int 69:94–101CrossRefPubMed

40.

Evans KD, Lau ST, Oberbauer AM, Martin RB (2003) Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta. Bone 32:268–274CrossRefPubMed

41.

McCarthy EA, Raggio CL, Hossack MD, Miller EA, Jain S, Boskey AL, Camacho NP (2002) Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model. Pediatr Res 52:660–670CrossRefPubMed

42.

Delos D, Yang X, Ricciardi BF, Myers ER, Bostrom MP, Camacho NP (2008) The effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta. J Orthop Res 26:153–164CrossRefPubMedPubMedCentral

43.

Bargman R, Huang A, Boskey A, Raggio C, Pleshko N (2010) RANKL inhibition improves bone properties in a mouse model of osteogenesis imperfecta. Connect Tissue Res 51:123–131CrossRefPubMedPubMedCentral

44.

Bargman R, Posham R, Boskey A, Carter E, DiCarlo E, Verdelis K, Raggio C, Pleshko N (2012) High- and low-dose OPG-Fc cause osteopetrosis-like changes in infant mice. Pediatr Res 72:495–501CrossRefPubMedPubMedCentral

45.

Bargman R, Posham R, Boskey AL, DiCarlo E, Raggio C, Pleshko N (2012) Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta. Osteoporos Int 23:1141–1150CrossRefPubMed

Title: Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-α
Authors: G. Brunetti
F. Papadia
A. Tummolo
R. Fischetto
F. Nicastro
L. Piacente
A. Ventura
G. Mori
A. Oranger
I. Gigante
S. Colucci
M. Ciccarelli
M. Grano
L. Cavallo
M. Delvecchio
M. F. Faienza
Publication date: 01-07-2016
Publisher: Springer London
Published in: Osteoporosis International / Issue 7/2016
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-016-3501-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-α

Abstract

Summary

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2016

Lower limb muscle strength is associated with poor balance in middle-aged women: linear and nonlinear analyses

Stability and degradation of fibroblast growth factor 23 (FGF23): the effect of time and temperature and assay type

Severe non-infective systemic inflammatory response syndrome, shock, and end-organ dysfunction after zoledronic acid administration in a child

Response to Fenton and Fenton: evidence does not support the alkaline diet

Continued decline in hip fracture incidence in Norway: a NOREPOS study

Vertebral fracture assessment by DXA is inferior to X-ray in clinical severe osteoporosis